Communiqués Merck & Co., Inc.

Actions

MRK

US58933Y1055

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:02 23/01/2026			Varia. 5j.	Varia. 1 janv.
108,18 ^USD	-0,92 %		-0,60 %	+2,77 %

22/01	MERCK & CO., INC. : JPMorgan Chase toujours à l'achat	ZM
22/01	SK Bioscience, MSD et Hilleman Laboratories font avancer le développement d'un vaccin contre le virus Ebola Zaïre avec un financement de la CEPI	CI

Communiqués

07/01	Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC	BU
07/01	Merck to Complete Acquisition of Cidara Therapeutics	BU
07/01	Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3	BU
05/01	Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
05/01	BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer	AQ
19/12	Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans	BU
19/12	Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma	AQ
18/12	Merck - KEYTRUDA plus Padcev Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery	AQ
17/12	KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery	BU
12/12	Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)	BU
12/12	Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030	AQ
08/12	Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program	AQ
04/12	FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)	BU
01/12	Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025	BU
26/11	Merck to Participate in the Citi 2025 Global Healthcare Conference	BU
26/11	Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference	BU
24/11	Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches	BU
22/11	Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer	BU
21/11	FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	BU
20/11	Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)	AQ
19/11	Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection	BU
19/11	European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union	BU
18/11	Merck Announces First-Quarter 2026 Dividend	BU
18/11	Merck Commemorates 5 Billion Mectizan Treatments Donated Over 38 Years	AQ
18/11	Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse Idées de trading

Filtres

A la une

Merck va acquérir Verona Pharma pour environ 10 milliards de dollars

Le 09 juillet 2025 à 18:30